Benzinga | Jan 31, 2022 07:59AM EST

NRx Pharmaceuticals Announces $25M Private Placement Priced At A Premium To Market Under Nasdaq Rules

RADNOR, Pa., Jan. 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules. The Company will also issue to the investors unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock. The purchase price for one share of common stock and one investment option to purchase one share of common stock is $3.195. The investment options have an exercise price of $3.07 per share, will be exercisable six months following issuance, and will have a term equal to five years following the date of initial exercise.